Sistema de Información Esencial en Terapéutica y Salud


Última actualización: 15/3/2021
SIETES contiene 93212 citas

 1 a 20 de 125 siguiente >>
Presentar resultados
Seleccionar todas
1. Cita con resumen
Anónimo. FDA approves elagolix for endometriosis pain. DIA Daily 2018:25 de julio. [Ref.ID 102722]
2. Cita con resumen
Anónimo. Strontium ranelate discontinued. Prescribing Advice for GPs 2017:1. [Ref.ID 101637]
3. Cita con resumen
Davis S, Martyn-St James M, Sanderson J, Stevens J, Goka E, Rawdin A, Sadler S, Wong R, Campbell F, Stevenson M, Strong M, Selby P, Gittoes N. A systematic review and economic evaluation of bisphosphonates for the prevention of fragility fractures. Health Technol Assess 2016;20:1-406. [Ref.ID 101044]
4. Cita con resumen
Munson JC, Bynum JPW, Bell J-E, Cantu R, McDonough C, Wang Q, Tosteson TD, Tosteson ANA. Patterns of prescription drug use before and after fragility fracture. JAMA Intern Med 2016;176:1531-8. [Ref.ID 100584]
5. Cita con resumen
Goss PE, Ingle JN, Pritchard KI, Robert NJ, Muss H, Gralow J, Gelmon K, Whelan T, Strasser-Weippi K, Rubin S, Sturtz K, Wolff AC, Winer E, Hudis C, Stopeck A, Beck JT, Kaur JS, Whelan K, Tu D, Parulekar WR. Extending aromatase-inhibitor adjuvant therapy to 10 years. N Engl J Med 2016;375:209-19. [Ref.ID 100399]
7. Cita con resumen
Yeh MW, Zhou H, Adams AL, Ituarte PHG, Liu IA, Haigh PI. The relationship of parathyroidectomy and bisphosphonates with fracture risk in primary hyperparathyroidism: an observational study. Ann Intern Med 2016:5 de abril. [Ref.ID 100114]
8. Cita con resumen
Leder BZ, Tsai JN, Uihlein AV, Wallace PM, Lee H, Neer RM, Burnett-Bowie S-A. Denosumab and teriparatide transitions in postmenopausal osteoporosis (the DATA-Switch study): extension of a randomised controlled trial. Lancet 2015;386:1147-55. [Ref.ID 99538]
10. Cita con resumen
Overton ET, Chan ES, Brown TT, Tebas P, McComsey GA, Melbourne KM, Napoli A, Hardin WR, Ribaudo HJ. Vitamin D and calcium attenuate bone loss with antiretroviral therapy initiation: a randomized trial. Ann Intern Med 2015;162:815-24. [Ref.ID 99296]
11. Cita con resumen
Anónimo. Osteoporosis postmenopáusica: un consenso necesario. Infac: Información Farmacoterapéutica de la Comarca 2015;23:27-32. [Ref.ID 99199]
12. Cita con resumen
Greenspan SL, Perera S, Ferchak MA, Nace DA, Resnick M. Efficacy and safety of single-dose zoledronic acid for osteoporosis in frail elderly women: a randomized clinical trial. JAMA Intern Med 2015;175:913-21. [Ref.ID 99183]
13. Cita con resumen
Anónimo. Traitements des cancers de l'enfance: effets indésirables à long terme. Prescrire 2015;35:348-52. [Ref.ID 99136]
14. Cita con resumen
LeBlanc ES, Chou R. Vitamin D and falls—Fitting new data with current guidelines. JAMA Intern Med 2015;175:712-3. [Ref.ID 98874]
15. Cita con resumen
Uusi-Rasi K, Patil R, Karinkanta S, Kannus P, Tokola K, Lamberg-Allardt C, Sievänen H. Exercise and vitamin D in fall prevention among older women. A randomized clinical trial. JAMA Intern Med 2015;175:703-11. [Ref.ID 98871]
16. Cita con resumen
Anónimo. Dilemmas in the management of osteoporosis. Drug Ther Bull 2015;53:18-21. [Ref.ID 98778]
17.Tiene citas relacionadas
Bischoff-Ferrari HA, Meyer O. Comparative effectiveness of pharmacologic treatments to prevent fractures: is this all we need to know?. Ann Intern Med 2014;161:711-23. [Ref.ID 98329]
18.Tiene citas relacionadas Cita con resumen
Crandall CJ, Newberry SJ, Diamant A, Lim Y-W, Gellad WF, Booth MJ, Motala A, Shekelle PG. Comparative effectiveness of pharmacologic treatments to prevent fractures: and updated systematic review. Ann Intern Med 2014;161:711-23. [Ref.ID 98328]
19. Cita con resumen
Anónimo. Drugs for postmenopausal osteoporosis. Med Lett Drugs Ther 2014;56:91-6. [Ref.ID 98234]
20. Cita con resumen
Costa J. Descans en el tractament amb bifosfonats: qui, quan i per quant temps.. Butlletí d'Informació Terapèutica 2014;25:1-9. [Ref.ID 97738]
Seleccionar todas
 1 a 20 de 125 siguiente >>